Soonchunhyang University Cheonan Hospital, Department of Neurosurgery, Cheonan, Korea.
Turk Neurosurg. 2022;32(5):845-853. doi: 10.5137/1019-5149.JTN.37422-21.2.
To conduct an animal experimental study to evaluate the safety and efficacy of the compression-resistant matrix (CRM) carrier for recombinant human bone morphogenetic protein-2 (rhBMP-2) in osteogenesis.
New moldable CRM carrier, and with rhBMP-2 (new CRM carrier with rhBMP-2) were prepared as the experimental groups. Pre-existing synthetic bone graft material was prepared as a control graft group. A total of 24 rabbits were included in the study. Defects were made and grafts were performed, and radiographic and histopathologic findings were evaluated to assess fusion.
In the computed tomographic scan, new bone formation was superior in 16.0%, 39.3%, 64.7%, and 81.1% of the total defect volume at 4, 8, 12, and 16 weeks in the new CRM carrier with rhBMP-2 group. In the new CRM carrier group, new bone formation was observed in 10.6%, 26.3%, 53.1%, and 71.4%, respectively. In the control graft group, new bone formation was observed in 10.1%, 26.6%, 53.4%, and 72.1%, respectively. On histopathologic evaluation, new CRM carrier with rhBMP-2 group showed better new bone formation compared with those of other groups.
The new moldable CRM carrier and the CRM carrier with rhBMP-2 showed preclinical safety and efficacy in new bone formation. In particular, the CRM carrier with rhBMP-2 was considered to be an effective bone graft material for bone fusion.
进行动物实验研究，评估抗压基质（CRM）载体在成骨中的安全性和重组人骨形态发生蛋白-2（rhBMP-2）的疗效。
制备新型可塑 CRM 载体和 rhBMP-2（新型 CRM 载体与 rhBMP-2）作为实验组。制备现有的合成骨移植材料作为对照移植组。共纳入 24 只兔子进行研究。制作缺损并进行移植，通过影像学和组织病理学检查评估融合情况。
在 CT 扫描中，新型 CRM 载体与 rhBMP-2 组在第 4、8、12 和 16 周时，总缺损体积的 16.0%、39.3%、64.7%和 81.1%出现新骨形成。新型 CRM 载体组分别观察到 10.6%、26.3%、53.1%和 71.4%的新骨形成。对照组分别观察到 10.1%、26.6%、53.4%和 72.1%的新骨形成。组织病理学评估显示，新型 CRM 载体与 rhBMP-2 组的新骨形成优于其他组。
新型可塑 CRM 载体和 rhBMP-2 的 CRM 载体在新骨形成方面表现出临床前的安全性和有效性。特别是，rhBMP-2 的 CRM 载体被认为是一种有效的骨融合骨移植材料。
